Important information on COVID-19 / Renseignements importants sur la COVID-19!

We are asking all patients and visitors coming to HSN to please wear a mask as an added step to reduce the spread of germs and protect vulnerable patients. Handmade masks are NOT acceptable. When you arrive at the hospital as a patient or care partner a hospital approved mask will be provided to you and you will be expected to wear it during your time at HSN to keep yourself, other patients and care partners and our staff, physicians, learners and volunteers safe.

Patients going for a procedure where they must remove the mask will be asked to keep it ready to be put back on once the procedure is completed.

Before coming to the hospital, please check our COVID-19 info page for updates.

    Mike Conlon, PhD

    Director, Epidemiology, Outcomes, and Evaluation Research
    Affiliate Scientist, Health Sciences North Research Institute
    Adjunct Professor, Human Sciences Division, Northern Ontario School of Medicine; Laurentian University; Lakehead University

    Dr. Mike Conlon was born and raised in Sudbury. He received a BSc degree from the University of Western Ontario, a MSc from Laurentian University, and a PhD in Epidemiology and Biostatistics from the University of Western Ontario. Dr. Conlon has been conducting cancer research at the Northeast Cancer Center for 20 years and in 2008 became the Director of the Epidemiology, Outcomes, and Evaluation at Health Sciences North’s Northeast Cancer Center.

    Research Interests

    Dr. Conlon and his team’s studies include traditional survey-based research, laboratory-based genetics, and health services research. The studies are large, diverse, and often collaborative in nature, with other researchers and clinicians at local, national, and international levels. Scientific findings are translated at scientific forums and published in scientific journals.  

    Dr. Conlon’s primary research focus includes examining risk factors for disease and treatment-based outcomes that are important in residents of the Northeast, and also explores important access to care issues in northeastern Ontario populations. Some of the projects involve, the analyses of biological samples obtained from an individual’s saliva, blood or tissues, which may help researchers and clinicians better tailor personal outcomes. 

    Current Funding

    • Northern Cancer Foundation
    • Northern Ontario Academic Medicine Association
    • Prostate Cancer Fight Foundation (PCFF) Telus Ride for Dad (Nipissing Chapter)

    Selected Publications

    • Conlon M, Hartman M, Ballantyne B, Aubin N, Meigs M, Knight A. (2015) Access to oncology consultation in a cancer cohort in northeastern Ontario.  Curr Oncol. 22(2)
    • Migliorati CA, Saunders D, Conlon MS, Ingstad HK, Vaagen P, Palazzolo MJ, Herlofson BB.( 2013) Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. J Am Dent Assoc. 144(4):406-14. 
    • Conlon MS, Bewick MA. (2011) Single nucleotide polymorphisms in CHRNA5 rs16969968, CHRNA3 rs578776, and LOC123688 rs8034191 are associated with heaviness of smoking in women in Northeastern Ontario, Canada. Nicotine Tob Res. 13(11):1076-83
    • Bewick MA, Lafrenie RM, Conlon MS. (2011) Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer. J Cancer Res Clin Oncol. (3):543-50. 
    • Conlon MS, Johnson KC, Bewick MA, Lafrenie RM, Donner A.(2010) Smoking (active and passive), N-acetyltransferase 2, and risk of breast cancer. Cancer Epidemiol. 34(2):142-9. 
    • Bewick MA, Conlon MS, Lafrenie RM. (2009) Haplotypes of XRCC1 and survival outcome in patients with metastatic breast cancer. Breast Cancer Res Treat.117(3):667-9. 
    • Bewick MA, Conlon MS, Lafrenie RM.(2008) Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat. 111(1):93-101. 
    • Bewick, MA, Conlon, MSC, Lafrenie, RM.(2006) Prognostic influence of polymorphisms in XRCC1, XRCC3, and CCND1 in patients with metastatic breast cancer. J Clin Oncology 24: 5645-5651, 
    • Conlon, M, Lightfoot, N, Bissett R, Steggles S, White, H, Jackson C. (1998). Predictors of re-attendance at an organised breast screening centre. Curr Oncol 5 (2): 85-90.
    • Conlon MS, Lightfoot NE, Bissett RJ, Fehringer GM.(2002) Cancer incidence and mortality in northeastern Ontario, 1991-1998. Can J Public Health 93(5):380-5.


    Telephone: 705-523-7300 ext.2601